Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABAA Receptors
Tremor and Other Hyperkinetic Movements · 2023
DOI: 10.5334/tohm.796 ↗At a glance
Journal article in Tremor and Other Hyperkinetic Movements, 2023. Written by Adrian Handforth and 3 co-authors. Institution: Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America. Major MEDLINE topics: Essential Tremor, Ketamine. Cited 8 times so far (Crossref); 70 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Prior work using GABAA receptor subunit knockouts and the harmaline model has indicated that low-dose alcohol, gaboxadol, and ganaxolone suppress tremor via α6βδ GABAA receptors. This suggests that drugs specifically enhancing the action of α6βδ or α6βγ2 GABAA receptors, both predominantly expressed on cerebellar granule cells, would be effective against tremor. We thus examined three drugs described by in vitro studies as selective α6βδ (ketamine) or α6βγ2 (Compound 6, flumazenil) receptor modulators.
Methods
In the first step of evaluation, the maximal dose was sought at which 6/6 mice pass straight wire testing, a sensitive test for psychomotor impairment. Only non-impairing doses were used to evaluate for anti-tremor efficacy in the harmaline model, which was assessed in wildtype and α6 subunit knockout littermates.
Results
Ketamine, in maximally tolerated doses of 2.0 and 3.5 mg/kg had minimal effect on harmaline tremor in both genotypes. Compound 6, at well-tolerated doses of 1–10 mg/kg, effectively suppressed tremor in both genotypes. Flumazenil suppressed tremor in wildtype mice at doses (0.015–0.05 mg/kg) far lower than those causing straight wire impairment, and did not suppress tremor in α6 knockout mice.
Discussion
Modulators of α6βδ and α6βγ2 GABAA receptors warrant attention for novel therapies as they are anticipated to be effective and well-tolerated. Ketamine likely failed to attain α6βδ-active levels. Compound 6 is an attractive candidate, but further study is needed to clarify its mechanism of action. The flumazenil results provide proof of principle that targeting α6βγ2 receptors represents a worthy strategy for developing essential tremor therapies. Highlights We tested for harmaline tremor suppression drugs previously described as in vitro α6βδ or α6βγ2 GABAA receptor-selective modulators. Well-tolerated flumazenil doses suppressed tremor in α6-wildtype but not α6-knockout mice. Compound 6 and ketamine failed to display this profile, likely from off-target effects. Selective α6 modulators hold promise as tremor therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America.
- Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States of America.
- Department of Neurology, Medical Neuroscience Cluster, Medical University of Vienna, Vienna, Austria.
- Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Vienna, Austria.
ORCID profiles: Adrian Handforth, Ram P Singh
Cite
APA
Handforth, A., Singh, R. P., Treven, M., & Ernst, M. (2023). Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABAA Receptors. Tremor and Other Hyperkinetic Movements. https://doi.org/10.5334/tohm.796
Vancouver
Handforth A, Singh RP, Treven M, Ernst M. Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABAA Receptors. Tremor and Other Hyperkinetic Movements. 2023. doi:10.5334/tohm.796
BibTeX
@article{Handforth2023,
author = {Handforth, Adrian and Singh, Ram P and Treven, Marco and Ernst, Margot},
title = {Search for Novel Therapies for Essential Tremor Based on Positive Modulation of α6-Containing GABAA Receptors},
journal = {Tremor and Other Hyperkinetic Movements},
year = {2023},
doi = {10.5334/tohm.796}
}
EUVIMED